Skip to main content

Paolini John F.'s Form 4 filing

Kiniksa Pharmaceuticals International, plc (KNSA) · filed Nov 4, 2025

Accession no.
0001741533-25-000003
Filed
Nov 4, 2025
Trade date
Oct 31, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.07M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paolini John F.CIK 0001741533Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 31, 2025Class A Ordinary ShareMOption exerciseAcquired+36,542$3.80+$138,859.697,866Direct
Oct 31, 2025Class A Ordinary ShareMOption exerciseAcquired+46,000$8.83+$406,180143,866Direct
Oct 31, 2025Class A Ordinary ShareSSaleDisposed−82,542$37.14−$3,065,609.8861,324Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 31, 2025Class A Ordinary ShareMOption exerciseDisposed−36,542$0.00$00Direct
Oct 31, 2025Class A Ordinary ShareMOption exerciseDisposed−46,000$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)